PMID- 35227269
OWN - NLM
STAT- MEDLINE
DCOM- 20220302
LR  - 20220308
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Feb 28
TI  - Development and validation of nomogram to predict very early recurrence of 
      combined hepatocellular-cholangiocarcinoma after hepatic resection: a 
      multi-institutional study.
PG  - 60
LID - 10.1186/s12957-022-02536-y [doi]
LID - 60
AB  - BACKGROUND AND OBJECTIVES: Combined hepatocellular cholangiocarcinoma (cHCC) has 
      a high incidence of early recurrence. The objective of this study is to construct 
      a model predicting very early recurrence (VER) (i.e., recurrence within 6 months 
      after surgery) of cHCC. METHODS: One hundred thirty-one consecutive patients from 
      Eastern Hepatobiliary Surgery Hospital served as a development cohort to 
      construct a nomogram predicting VER by using multi-variable logistic regression 
      analysis. The model was internally and externally validated in a validation 
      cohort of 90 patients from Mengchao Hepatobiliary Hospital using the C 
      concordance statistic, calibration analysis, and decision curve analysis (DCA). 
      RESULTS: The VER nomogram contains microvascular invasion (MiVI), macrovascular 
      invasion (MaVI), and CA19-9 > 25 mAU/mL. The model shows good discrimination with 
      C-indexes of 0.77 (95% CI: 0.69-0.85) and 0.76 (95% CI: 0.66-0.86) in the 
      development cohort and validation cohort respectively. Decision curve analysis 
      demonstrated that the model is clinically useful and the calibration of our model 
      was favorable. Our model stratified patients into two different risk groups, 
      which exhibited significantly different VER. CONCLUSIONS: Our model demonstrated 
      favorable performance in predicting VER in cHCC patients.
CI  - (c) 2022. The Author(s).
FAU - Wu, Yijun
AU  - Wu Y
AD  - Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Liu, Hongzhi
AU  - Liu H
AD  - Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Zeng, Jianxing
AU  - Zeng J
AD  - Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Chen, Yifan
AU  - Chen Y
AD  - Shengli Clinical Medical College of Fujian Medical University, Fuzhoum, People's 
      Republic of China.
FAU - Fang, Guoxu
AU  - Fang G
AD  - Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Zhang, Jinyu
AU  - Zhang J
AD  - Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China.
FAU - Zhou, Weiping
AU  - Zhou W
AD  - Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, 
      Second Military Medical University, Shanghai, 200438, People's Republic of China.
FAU - Zeng, Yongyi
AU  - Zeng Y
AD  - Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian 
      Medical University, Fuzhou, 350025, People's Republic of China. 
      lamp197311@126.com.
FAU - Liu, Jingfeng
AU  - Liu J
AD  - Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, No. 420, Fuma 
      Road, Fuzhou, 350014, Fujian, People's Republic of China. drjingfeng@126.com.
AD  - The Big Data Institute of Southeast Hepatobiliary Health Information, Mengchao 
      Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's 
      Republic of China. drjingfeng@126.com.
LA  - eng
GR  - 2020-WS-57/Fuzhou Science and Technology Bureau project/
GR  - 2020-WS-92/Fuzhou Science and Technology Bureau project/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220228
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
SB  - IM
MH  - *Bile Duct Neoplasms/pathology/surgery
MH  - Bile Ducts, Intrahepatic/pathology
MH  - *Carcinoma, Hepatocellular/pathology/surgery
MH  - *Cholangiocarcinoma/pathology/surgery
MH  - Hepatectomy
MH  - Humans
MH  - *Liver Neoplasms/pathology/surgery
MH  - Nomograms
MH  - Retrospective Studies
PMC - PMC8883704
OTO - NOTNLM
OT  - Combined hepatocellular-cholangiocarcinoma (cHCC)
OT  - Nomogram
OT  - Prognosis
OT  - Very early recurrence
COIS- The authors declare that they have no competing interests.
EDAT- 2022/03/02 06:00
MHDA- 2022/03/03 06:00
PMCR- 2022/02/28
CRDT- 2022/03/01 05:42
PHST- 2021/11/23 00:00 [received]
PHST- 2022/02/18 00:00 [accepted]
PHST- 2022/03/01 05:42 [entrez]
PHST- 2022/03/02 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2022/02/28 00:00 [pmc-release]
AID - 10.1186/s12957-022-02536-y [pii]
AID - 2536 [pii]
AID - 10.1186/s12957-022-02536-y [doi]
PST - epublish
SO  - World J Surg Oncol. 2022 Feb 28;20(1):60. doi: 10.1186/s12957-022-02536-y.